Hydromorphone
Dilaudid, Hydromorphone (hydromorphone) is a small molecule pharmaceutical. Hydromorphone was first approved as Dilaudid-hp on 1984-01-11. It is used to treat cough and postoperative pain in the USA. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target kappa-type opioid receptor and delta-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Dilaudid, Hydromorphone (discontinued: Dilaudid, Exalgo, Hydromorphone, Palladone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydromorphone hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DILAUDID | Fresenius Kabi | N-019034 RX | 2009-04-30 | 5 products, RLD, RS |
| HYDROMORPHONE HYDROCHLORIDE | Hikma Pharmaceuticals | N-217812 RX | 2023-12-14 | 1 products, RLD, RS |
| HYDROMORPHONE HYDROCHLORIDE | Hospira | N-200403 RX | 2011-12-01 | 5 products |
| DILAUDID | Rhodes Pharmaceuticals | N-019891 RX | 1992-12-07 | 1 products, RLD, RS |
| DILAUDID | Rhodes Pharmaceuticals | N-019892 RX | 1992-12-07 | 3 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dilaudid | New Drug Application | 2024-01-08 |
| exalgo | New Drug Application | 2013-01-28 |
| hydromorphone hcl | unapproved drug other | 2014-08-20 |
| hydromorphone hydrochloride | New Drug Application | 2024-11-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postoperative pain | — | D010149 | G89.18 |
| cough | HP_0012735 | D003371 | R05 |
Agency Specific
FDA
EMA
No data
Clinical
Clinical Trials
311 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | 1 | 5 | 5 | 38 | 21 | 69 |
| Pain | D010146 | EFO_0003843 | R52 | 5 | 7 | 16 | 16 | 13 | 57 |
| Acute pain | D059787 | — | R52 | 3 | 7 | 7 | 7 | 4 | 27 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 7 | 8 | 1 | 2 | 4 | 21 |
| Cancer pain | D000072716 | — | G89.3 | — | 2 | 10 | 4 | 3 | 19 |
| Chronic pain | D059350 | HP_0012532 | — | 2 | 1 | 7 | 5 | — | 15 |
| Neoplasms | D009369 | — | C80 | 1 | 3 | 2 | 4 | 3 | 13 |
| Analgesia | D000698 | — | — | 2 | 4 | 2 | 2 | — | 10 |
| Healthy volunteers/patients | — | — | — | 4 | — | — | 2 | 1 | 7 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | 1 | 2 | 3 | 6 |
Show 87 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | 3 | — | 1 | 4 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | 3 | — | — | 3 |
| Heroin dependence | D006556 | EFO_0004240 | — | — | — | 1 | — | 2 | 3 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | — | 1 | — | 1 | 2 |
| Obstetrical anesthesia | D000773 | — | — | 1 | — | 1 | — | — | 2 |
| Mucositis | D052016 | EFO_1001898 | — | — | 1 | 1 | — | — | 2 |
| Hernia | D006547 | HP_0100790 | K40-K46 | — | — | 1 | — | 1 | 2 |
| Spinal anesthesia | D000775 | — | — | — | — | 1 | — | 1 | 2 |
| Cystectomy | D015653 | — | — | — | — | 1 | — | — | 1 |
| Intrahepatic cholestasis | D002780 | — | — | — | — | 1 | — | — | 1 |
Show 15 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | 2 | — | — | 1 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 2 | 3 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | 1 | 2 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 1 | 1 | — | — | — | 2 |
| Cannabis | D002188 | — | — | — | 2 | — | — | — | 2 |
| Pruritus | D011537 | HP_0000989 | L29 | — | 1 | — | — | — | 1 |
| Vertigo | D014717 | — | H81.39 | — | 1 | — | — | — | 1 |
| Mastodynia | D059373 | EFO_1001366 | N64.4 | — | 1 | — | — | — | 1 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 1 | — | — | — | 1 |
| Pancreatitis | D010195 | HP_0001733 | K85 | — | 1 | — | — | — | 1 |
Show 14 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Musculoskeletal pain | D059352 | — | — | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Spinal stenosis | D013130 | EFO_0007490 | M48.0 | 1 | — | — | — | — | 1 |
| Spondylosis | D055009 | — | M47 | 1 | — | — | — | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | — | — | — | — | 1 |
| Chronic limb-threatening ischemia | D000089802 | — | — | 1 | — | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Delirium | D003693 | — | R41.0 | — | — | — | — | 4 | 4 |
| Local anesthesia | D000772 | — | — | — | — | — | — | 3 | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 2 | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 2 | 2 |
| Emergence delirium | D000071257 | — | — | — | — | — | — | 2 | 2 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 2 | 2 |
| Conduction anesthesia | D000765 | — | — | — | — | — | — | 2 | 2 |
| Drug-seeking behavior | D058999 | — | — | — | — | — | — | 2 | 2 |
| Nerve block | D009407 | — | — | — | — | — | — | 1 | 1 |
| Cardiac surgical procedures | D006348 | — | — | — | — | — | — | 1 | 1 |
Show 34 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Hydromorphone |
| INN | hydromorphone |
| Description | Hydromorphone is a morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class. It has a role as an opioid analgesic and a mu-opioid receptor agonist. It is a morphinane alkaloid and an organic heteropentacyclic compound. It derives from a hydride of a morphinan. |
| Classification | Small molecule |
| Drug class | Opioid |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5 |
Identifiers
| PDB | — |
| CAS-ID | 466-99-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL398707 |
| ChEBI ID | 5790 |
| PubChem CID | 5284570 |
| DrugBank | DB00327 |
| UNII ID | Q812464R06 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Hydromorphone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,934 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dilaudid, Exalgo, Hydromorphone hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
85,361 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use